Pathwork Diagnostics Inc. Appoints Lee McCracken as CEO
News Nov 06, 2012
"On behalf of Pathwork's board and investors, I am delighted to welcome Mr. McCracken to the Pathwork team," said Peter Klemm, Ph.D., Chairman of the Board. "Lee, with his considerable leadership and corporate development experience, is an outstanding choice to lead Pathwork to the next level of success," said Dr. Klemm.
"I am truly pleased to join Pathwork at this exciting time in the company's history," said Mr. McCracken. "I believe the Tissue of Origin Test is positioned to become the standard of care for difficult-to-diagnose cancer tumors. Furthermore, Pathwork's proprietary informatics platform - which enabled the creation of the Tissue of Origin Test - has significant potential for developing new products. I look forward to leading the company's next stage of growth."
Lee McCracken, who serves on the company's Board of Directors, has over 20 years of experience in the life sciences, spanning novel high-value diagnostics, specialty pharmaceuticals and platform technologies in both private and public companies. He joins Pathwork following seven years as Corporate Head of Business Development at Prometheus Laboratories, a leading personalized healthcare company in gastroenterology and oncology. Prior to Prometheus, Mr. McCracken served as Senior Vice President of Pharmaceutical Business Development at Diversa Corporation. Earlier in his career, he held leadership roles with GenStar Therapeutics, CombiChem and Allergan Americas.
Before pursuing operating and corporate development roles in the life sciences, Mr. McCracken was a venture capitalist with 3i Capital and Union Venture. Mr. McCracken holds a B.S. from Santa Clara University, a Master of Computer Science from University of Dayton and an M.B.A. from UCLA Anderson School of Management.
Screening for Disease or Toxins in a Drop of BloodNews
Scientist have developed a multinozzle emitter array (MEA), a silicon chip that can dramatically shorten the time it takes to identify proteins, peptides, and other molecular components within small volumes of biological samples.READ MORE
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE
Fabric Genomics Partners to Improve Pediatric CareNews
Partnerships with Genomics England, Rady Children's Institute for Genomic Medicine, and The Utah Genome Project demonstrate diagnostic utility of Fabric Genomics' algorithm-based genome analysis.READ MORE